BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M

BIOLARGO, INC.

Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.
Net loss of $15.2M vs. $4.3M in prior year; cash balance $3.9M at year end.
Engineering services revenue from third parties grew 98% to $2.0M.
Subsidiary Clyra Medical secured first stocking order for ViaCLYR wound irrigation solution.
PFAS treatment system installed in New Jersey; PFAS breakthrough featured in Chemical Engineering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.